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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is the fourth cause of death in western countries. Its
final stage has clearly been forgotten by medical research in recent years. There exists consensus regarding the
need to integrate palliative care in assisting these patients, but the difficulty in establishing a prognosis for the
disease, establishing limits for life support measures, the lack of information about the disease’s natural course and
ignorance as to the most effective health-care structure for these patients’ palliative treatment may be responsible
for their late inclusion or non-inclusion in specific programmes. The main purpose of this work is to find out the
natural background of patients with stage IV COPD and the main prognostic factors that influence these patients’
survival.
Methods/design: Prospective observational study of a home patient cohort with stage IV COPD sent from Neumology
consultations and Palliative Care Unit in La Paz Hospital in Madrid and Primary Care Health Centres in the area to the
palliative care home support team. The goal is to study socio-demographic variables, prognosis, nutritional status, use
of health resources, perceived quality of life, functionality, main symptomatology, use and effectiveness of opioids,
adherence to treatment, prognostic information regarding the disease, information given by professionals, advance
directives, social backup requirements and overburden level of the main caregiver.
Discussion: The HOLD study is a project aimed at finding out the prognostic factors and evolution of the disease
COPD in its most advanced stage. The final goal is to improve the health and quality of life, in a personalised,
integral way up to end of life and explore and foster communication with patients, as well as their participation
and collaboration in decision-taking. The HOLD study can help us better understand what these patients’ real
palliative and care needs are, in order to more efficiently organise their treatment at end of life.
Keywords: COPD, Palliative care, Homecare, End of life
Background
Chronic Obstructive Pulmonary Disease (COPD) is cur-
rently the fourth cause of death in western countries [1,
2], and it is, among the main ones, the one that has most
increased in recent years [1]. The advanced stages of the
disease are characterised by significant morbidity. The
high frequency of symptoms, functional deterioration
and the large number of exacerbations lead to major de-
terioration in patients’ quality of life, to a high rate of
hospitalisations and, in general, to a significant increase
in care and treatment costs [3, 4].
The final stage of progressive, incurable diseases have
been ignored by medical research until recent years. In
general, patients in more advanced states have been ex-
cluded from research work. However, only a proper de-
scription of the final stage of these diseases can let us
better evaluate patients’ needs and the care and treat-
ment they should receive [5]. The results of the SUP-
PORT study [6] showed the significant deficiencies in
the care of these ill people which comprise both the
treatment of symptoms and the consideration of pa-
tients’ advance directives.
There is consensus regarding the need to integrate pal-
liative care in attending to patients with COPD. In re-
cent years, practically all scientific organisations that
include professionals involved in attending these patients
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and different health-care institutions have made major
efforts to try to divulge the need to apply the principles
of palliative care to these patients [7–11]. The main
problem in implementing palliative care programmes for
patients with advanced COPD lies in establishing appro-
priate prognostic criteria. Some prognostic indexes have
been created to help in selection processes. The BODE
index [12] is the most widespread [13, 14]. However,
even patients with very high values on the BODE index
may survive for years. The patient cohort with Advanced
Chronic Respiratory Disease in the SUPPORT study [15]
showed how patients with worse self-perception of their
state of health survived less. Subsequently, other works
have shown how ratings obtained by questionnaires on
health-related quality of life, both general and specific, are
correlated with survival [16, 17]. The difficulty in estimat-
ing the survival of patients with advanced COPD may
mean that they receive sub-optimal treatment.
Despite showing a comparable frequency of symptoms
and, in general, similar needs, when end-of-life care re-
ceived by the patients with lung cancer is compared with
that of advanced COPD sufferers, favourable results are
always obtained for oncological patients [18]. In these
studies, patients with advanced COPD show: worse health
and social care, worse diagnostic and prognostic informa-
tion, worse symptomatological control, less participation
in clinical decision-taking and greater use of aggressive
measures to increase survival [15, 19–21]. In a study car-
ried out by Heyland and cols. [22], patients with
advanced-stage COPD reported, as high-priority needs,
good symptomatic control, not being a burden for their
family, receiving appropriate information which includes
benefits and risks of the treatment, and having access to a
doctor to ask questions regarding their disease.
In short, the difficulty in establish a prognosis, the diffi-
culty in limiting advanced life-support measures and the
lack of information about the disease’s natural course can
be responsible for the these patients’ late inclusion or ex-
clusion in palliative care programmes. In recent years, au-
thors have recommended, in order to improve this
situation, including palliative care as part of the standard
team responsible for monitoring patients in advanced
stages, in such a way that a palliative approach to the dis-
ease starts early, regardless of their prognosis [23].
Continuity of care is a key element in offering proper
health care to patients with advanced diseases [24]. A
single team, especially if it is hospital-based, cannot re-
spond to patient’s needs under any circumstance. For
this reason, coordination is essential with different care
resources. Home care allows attention to be given dir-
ectly to advanced-COPD patients [25] whose functional
deterioration prevents them from leaving home and at-
tending consultations. It would therefore be a key factor
for ensuring continuity of care.
There barely exist works on the most effective health
structure for attending to end-of-life for these patients
[24], nor on the natural background of patients with ad-
vanced COPD. These kinds of studies can provide us
with information about symptomatic burden, quality of
life and real needs of health resources for these patients.
This information would let us develop more effective
health structures and improve the care that these pa-
tients receive, offering them and their families more
realistic expectations as the disease progresses and they
approach the moment of death.
The main goal of the study is to find out the natural
background of stage-IV COPD patients, from when the
advanced disease obliges them to stay at home, prospect-
ively evaluating the evolution of symptoms, quality of
life and the use of health resources in the final stage of
the illness.
The specific goals of this work are:
1. Find out the main prognostic parameters in these
patients survival and in the evolution of their quality
of life
2. Assess the level of information to patients with
COPD and to their families, the percentage of
patients with advance directive documents and the
level of information given by professionals and
included in their reports
3. Find out the evolution of COPD patients
functionality, describe the most important
symptoms, paying special attention to dyspnoea, as
well as its level of control and co-morbidity
4. Evaluate use of health resources in advanced stages
of COPD patients monitored at home
5. Evaluate perceived quality of life and its evolution in
the advanced stage of the COPD at home
6. Estimate the use of opioids in standard clinical
practice for treating dyspnoea and their effectiveness
in controlling dyspnoea
7. Assess the level of therapeutic compliance and
inhalant techniques and the use of home oxygen
therapy
8. Find out the main caregiver’s social support needs
and level of over-burden
Methods
Design
Prospective observational study of a stage-IV COPD pa-
tient cohort immobilised at home.
Participants and recruitment
The study will include patients sent to the Palliative
Home Care Support Team (PHCST) from the Neumol-
ogy Service in La Paz Hospital, from the Palliative Care
Unit, or from Primary Health Care diagnosed with stage
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IV COPD who are going to be monitored at home and
who fit the criteria for inclusion, exclusion and with-
drawal (Table 1).
Data collection
The information will be collected during programmed
visits to the patients’ home, by PHCST researchers.
In the initial visit, apart from checking that the patient
complies with the criteria for inclusion and exclusion,
and the signature of informed consent, information will
be gathered on the patient’s variables (listed below).
Monitoring visits will be carried out quarterly up to a 2-
year maximum (Fig. 1).
Variables
During the different programmed home visits, the fol-
lowing variables will be collected by the research team:
Socio-demographic variables
Age, sex, education level, labour situation, family unit,
relationship with main caregiver.
Survival variables
– Survival time: this will be calculated as from the
registration date of the disease’s stage IV diagnosis
and date of death. Survival will also be calculated as
from the date of inclusion in the study.
– Place of death (Home/Palliative Care Unit/Hospital
Ward/Residence/Emergency Room).
Personal background
Smoking, packets/year, age when smoking started, car-
diac insufficiency, high blood pressure, diabetes, depres-
sion, anxiety disorder, flu and pneumococcal vaccine,
Pseudomona aerogynose isolation.
Prognostic variables
– Charlson comorbidity index [26]: absence of
comorbidity is considered: 0–1 points; low
comorbidity: 2 points; and high: > 3 points. Since
monitoring will be less than 5 years this will not be
corrected by age.
– BODE Index [12]: calculations will collect indexes of
body mass, last FEV1 upon discharge, Modified
Medical Research Council dyspnoea scale and the
6-min walk distance at the end of consultations.
Scored from 0 to 10 points.
– Surprise question: formulated as “would you be
surprised if this patient dies the next year? YES/
NO”. The care team will make this question after
the patient’s first home evaluation [27].
– Palliative Prognostic Score: prognostic scale that
divides patients into three risk groups: A (>70 %
probabilities of survival at 30 days) if the score is
between 0–5.5; B (30-70 % survival at 30 days) if the
score is between 5.6 and 11; and C (probability less
than 30 % at 30 days) if the score is between 11.1
and 17.5 [28].
– Nutritional state: this will be obtained via three
variables. The body mass index, albumin obtained by
blood analysis and Mini Nutritional Assessment
(MNA): a nutritional screening and assessment
instrument for the elder population [29], validated in
Spanish [30].
Variables to determine the use of health resources and
social support needs in the final stage
– Telephone calls: Made to the PHCST, Primary care
health team (PCHT), emergency calls, and
tele-assistance. Caregivers will be asked about calls
made since the previous visit.
– Home visits: Carried out by the PHCTS (collected
by care/research team),
– Visits made by primary care doctor in homes and
health centres (asking the patient and/or carer and
checking in the computer programme AP-Madrid
visits registered by PCHT.
– Hospitalisations/hospital emergencies: collected by
reports of admissions by hospital services. This will
also register the number of days hospitalised.
– Admissions to Palliative Care Units/Residences:
this will register the number of days admitted up
to death. It will be recorded by telephoning the
centre.
Variables to “Evaluate perceived quality of life”
– St. George’s questionnaire regarding health-related
quality of life, validated in Spanish [31]: This will be
Table 1 Criteria for selecting patients
Criteria for inclusion Criteria for exclusion Criteria for withdrawal
• Over 18 years old
• Clinical diagnosis of stage-IV COPD according
to GOLD 2007 guidelines
• Functional deterioration that hampers
monitoring in external consultations or PPS
below 70
• Severe cognitive deterioration or severe
mental illness
• Diagnosed with lung cancer or cystic fibrosis
• Impossibility of maintaining home care due
to absence of main caregiver
• Not fluent in Spanish language
• Suffering from lung cancer, of recent appearance
during monitoring
• Change of habitual residence outside the Northern
Community of Madrid Care Directorate
• Admission to a Palliative Care Unit
• Patient decides to abandon the study
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checked after being carried out to evaluate its full
implementation. Score variations of 4 points are
considered clinically significant.
– Questionnaire regarding health-related quality of life:
COPD Assessment Test (CAT) [32]. Score from 0 to
40. It divides patients into low-impact levels (<10
points), medium-impact (10 to 20 points), high-
impact (more than 20 points) or very high (more
than 30 points). Self-fulfilment will be supervised by
the health team. Variations of 2 points in the score
are considered clinically significant.
Variables to “Evaluate the functionality of COPD patients”
– Palliative Performance Scale (PPS) [33]: Functional
assessment scale based on the Karnofsky scale. It
scores from 0 to 100 % where 0 % is the patient’s
death and 100 % means a healthy patient able to
walk around.
– Barthel index (BI) [34]: The BI is an ordinal scale
used to measure performance in activities of daily
living (ADL). It aims to assign each patient a
score of their level of dependence to carry out a
Fig. 1 Shows the general outline of the study’s data collection
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series of basic activities. It uses ten variables
describing ADL and mobility. The values assigned
to each activity depend on the time used to carry
them out and need for help to do so [8, 10].
– International Physical Activity Questionnaire, short
version [35]: This provides information about time
used when walking, activities of moderate and
vigorous intensity and in sedentary activities.
Physical activity is described in Metabolic Equivalent
Tasks (METs), where an equivalent metabolic task is
equal to the energy expended while resting, and are
expressed in METs minutes/week. The IPAQ
considers moderate-intensity activities to be those of
3–6 METs and vigorous to those greater than 6
METs. The questionnaire also classifies physical
activity in three levels: lowers, moderate and high.
Finally, the questionnaire includes an additional
indicator of sedentary activity that does not add to
the score, and which corresponds to time sitting
down, measured separately for working days and
weekends.
A drop in functionality will be evaluated by unit of
time in order to evaluate the linearity of the loss and its
relation with survival
Variables to “evaluate the most important symptoms, level
of control and co-morbidity”
– Edmonton Symptom Assessment System (ESAS) in
its validated Spanish version [36]: list of 10
numerical scales from 1 to 10, which evaluate the
average intensity of 10 symptoms at a certain time.
The patient is requested to indicate the number that
best represents the intensity of each symptom. If the
patient were unable to indicate it correctly, he or
she will be asked about each symptom and to qualify
it as zero, slight, moderate, severe or very severe,
assigning for each of these answers a score of: 0
nothing, 2 for slight, 5 for moderate, 7 severe and 10
very severe.
– Dyspnoea Scale of the British Medical Research
Council (MRC) [37]: this evaluates the level of
dyspnoea from 0 to 4 (level 0: the dyspnoea only
begins with maximum effort; up to level 4: the
dyspnoea exists while resting and prevents the
patient from leaving his or her home). This will be
evaluated by asking the patient during a clinical
interview.
– The Hospital, Anxiety and Depression Scale [38]:
This consists of 14 items. It measures mood with
two scales, one for anxiety and another for
depression. According to the score obtained it is
divided into non-case of anxiety/depression (0–7
points), doubtful case of anxiety/depression [8–10]
and case of anxiety/depression if a score above 11
points is obtained.
Number of exacerbations: this will register the number
of exacerbations attended during the patient’s monitor-
ing by the PHCST and exacerbations that have required
hospitalisation will be noted.
Variables to “Evaluate the use of opiates in standard
clinical practice to treat dyspnoea and their effectiveness in
controlling dyspnoea”
– Use of opioids: use yes/no, date prescribed,
professional who prescribes their use.
– Effectiveness: The use of opioids will be considered
effective in controlling dyspnoea if it decreases in
the ESAS by at least 2 points with the response
remaining for at least 3 days. A check-up will be
carried out on the third day of the opiate’s
prescription to ask about the dyspnoea. Time of
treatment with opioids will also be evaluated,
including date of treatment withdrawal and reason
for doing so.
Variables to “Evaluate the level of therapeutic compliance
and the inhalant technique and home use of oxygen
therapy”
– Morinsky-Green Questionnaire validated in Spanish
[39]: This evaluates patients’ attitudes regarding the
treatment. Patients who respond correctly to the
four questions it comprised will be qualified as
compliant. An inadequate response qualifies the
patient as non-compliant.
– Inhaler type and inhalant technical: This will register
the type of inhalers that the patient uses and the
inhalant technique will be evaluated, classifying it
as correct or incorrect according to the
recommendations of the Spanish Neumology and
Thoracic Surgery Society (SEPAR), for the use of
inhalers [38].
– Variables relating to oxygen therapy: This will
record the number of hours of oxygen therapy the
patient has used the previous day, the number of
litres per minute determined from neumology and
the number of litres per minute administered by the
patient’s concentrator, checking the flow meter
during the visit. It will also evaluate the increase in
oxygen requirements by time unit with the aim of
evaluating reality of loss and its relationship with
survival. Use of non-invasive ventilation mechanics
and number of hours of ventilation will be also
evaluated.
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Variables to “Evaluate the level of information to COPD
patients and their families”
a) Information given by the professional: This will
register the patient’s reports or record. The patient
will be considered as:
– Informed by the professional of the diagnosis: if
the reports show that the patient has been
explained that he/she suffers from COPD and its
level of severity.
– Informed by the professional of the prognosis: if
the reports show that the limitation of life
expectancy has been explained, conditioned by
the base disease.
– Partially informed: If there exists registered
information as regards diagnosis and prognosis
but it is incomplete (understanding complete to
mean as described in the previous point).
– Not informed: if it is shown that information has
not been passed on to the patient as regards the
diagnosis or prognosis. Apart from background,
this will also register or by contacting the
responsible professional the reason for
non-information (not requirement of information
from the patient, difficulties in professional/
patient communication, pact of silence, other).
– Not referred: the patient’s clinical record or
reports do not register whether information has
been given to the patient regarding the diagnosis
and/or prognosis.
b) Information perceived by the patient: During the
clinical interview, the patient’s knowledge will be
evaluated as regards their diagnosis and prognosis,
classifying the patient as:
– Expert: We will consider the patient to be an
expert of the diagnosis if on being asked which
disease they are suffering, the patient refers to:
“COPD”, “chronic bronchitis”, “bronchitis”, “lung
disease”, “bronchial disease”, “chronic lung
disease”. They must also express its chronic,
irreversible nature: “It is chronic”, “it is
incurable”, “it is irreversible”, “it is forever”, “it’s
for life”, “it has no solution”. We will also consider
the patient to be an expert on the prognosis if they
consider that their life expectancy is limited as a
consequence of their disease.
– Partially expert: During the interview, the patient
does not know their diagnosis or prognosis or
they partially know the information as regards
diagnosis or prognosis.
– Non-expert: The patient does not know either
the diagnosis or the prognosis.
– Not explored: Not approached during the
interview by the team. The reason will be given
(information not required by the patient,
difficulties in the professional/patient
communication, pact of silence, other).
c) Advance directive document: The patient or his/her
family will be asked as to the existence of this
document, classified in the following categories:
– Non- existence: document of advance directives
does not exist in writing.
– Unregistered legal document: legal document of
advance directives exists but it has not been
deposited in any official register of advance
directives.
– Registered legal document: legal document of
advance directives exists in an official register of
advance directives.
– Document prepared with the team: the document
of advance directives in writing has been
prepared and included in the patient's clinical
record or in a separate document during our
team’s monitoring and with our advice. The
category prepared with the Team is not exclusive
from unregistered or registered legal document.
Variables to “Evaluate the main carer’s social support needs
and level of over-burden” registering the following
variables
– Gijón abbreviated and modified scale of socio-family
evaluation [40]: This evaluates 3 items: family
situation, relationships and social contacts and social
network support.
– Zarit Burden inteview short version [41]:
questionnaire of 7 items where the caregiver assigns
a frequency corresponding to a score of 1 to 5. If the
sum of the scores is greater than or equal to 17 it
would indicate caregiver overburden.
Calculation of sample size and data analysis
It is estimated that in the Community of Madrid (the
population is around 6,400,000 inhabitants)., every year
500 COPD patients enter the final stage of the disease.
Coverage by the team of professional researchers is for a
population of around 1,000,000, so it is estimated that at
most up to 77 patients/year could be included and with
a forecast to include approximately 70 % of these pa-
tients from the area covered by the ESAPD and a 2-year
period of recruitment. 108 patients would be included,
which would guarantee adequate representation of this
population. It is calculated that losses could mean 10-
20 % of these patients, so the final sample size is consid-
ered to be between 80 and 100 patients.
The information included in the data-collection book
will be recorded in a local database. This database will
have the necessary protection measures and it will only
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be accessible by the project researchers. Prior to the stat-
istical analysis, an analysis of the quality of the data
collected will be carried out to purge any possible tran-
scription errors.
Statistical analysis
Most of the goals will be met with descriptive statistics,
summarising the quantitative variables by means of aver-
age, standard deviation and minimum and maximum
values. For asymmetric distributions, the median will be
used as a centralisation measure and percentiles 25 and
75 as measures of dispersion. For categorical variables,
their absolute frequency and distribution of frequencies
will be expressed. Evaluation of survival will be carried
out by taking into account the date when home moni-
toring began and date of death (or departure from the
study), using a Cox proportional hazards model to
examine the independent effect of the prognostic vari-
ables studied.
The statistical programme SPSS version 21.0 will be
used.
Discussion
The HOLD study is a project focused on finding out the
factors prognostic and the evolution of the disease
COPD in its most advanced stage. In recent years, other
works have described the advanced stage of other or-
ganic insufficiencies and neuro-degenerative diseases
[42, 43]. We need to have the best scientific evidence to
respond to the needs of patients suffering from advanced
diseases [5]. The final goal should be to improve health
and quality of life in a personalised, integral way until
end of life. Respiratory diseases represent the second
cause as regards the type of cases attended in hospitals,
accumulating 11.6 % of discharges (only behind those of
the circulatory system), they are the fourth cause of
death and are also among the first four diagnoses in glo-
bal costs for the Spanish health system, representing the
largest use of health resources and with the greatest in-
tensity in the elderly population, as is the case of most
of these patients and in the final stages of the disease
[44]. In economic terms, it is estimated that at out-
patient level, COPD represents an expense of 528 mil-
lion euros a year. By patient and severity, a patient with
serious COPD generated an expense of 3,335 euros a
year, a patient with moderate COPD 2,275 euros/year
and a patient with slight COPD 1,650 euros/year [44].
The proposed investigation would provide better know-
ledge on achieving the system’s sustainability through ra-
tional use of all available resources, and a health care
that goes from primary care and specialised attention to
home and palliative care.
A very significant goal of this study is to find out and
encourage communication with patients, as well as their
participation and collaboration in decision-taking. In-
volving patients in decision-taking is not only a right but
also improves therapeutic results by avoiding treatment
considered to be disproportionate and improving pa-
tients’ quality of life [45–47].
COPD has a major impact on quality of life due to
dyspnoea, respiratory insufficiency, exacerbations and
hospitalisations, leading to a reduction in productive ac-
tivities, social relationships, significant dependence and
social isolation. Our study seeks to contribute new
knowledge regarding these patients’ needs and possible
strategies to address them. In particular, the aim is to ex-
plore the use of opioids in these patients’ dyspnoea [48].
In conclusion, the study of advanced COPD’s natural
background can help us to better understand what are
the real assistance and palliative needs of these patients
at end of life, with the aim of more efficiently organising
their care at end of life.
Limitations of the study
Our study has some possible limitations in design as
regards the inclusion of participants and the parameters
evaluated.
Firstly, the selection of patients mainly on the refer-
ence Neumology Services and the sample obtained may
not be representative of the patients immobilised at
home with a diagnosis of advanced (stage IV) COPD. It
could therefore be necessary to use a recruitment strat-
egy that also takes into account primary care doctors to
access most of the patients in the area with these
characteristics.
Secondly, as regards the variables evaluated, the regis-
tration dates of the diagnosis may not be totally exact, as
they are based mainly on clinical registrations, and it is
known to be a disease that is under-diagnosed and
under-registered. However, most clinical information
will be obtained directly from the patient or from the
clinical record and the close, constant monitoring of
these patients by the research team.
Thirdly, there may be losses in monitoring for reasons
of institutionalisation, admittance or change of home.
However, we think that the relationship of the ESAPD not
only with the patient but with his or her close family en-
vironment, would allow this information to be recovered.
Ethical aspects
Patients will be requested, freely and voluntarily, to give
informed consent in writing if they are interested in tak-
ing part in the study, after reading the information sheet
and clarifying any possible doubt they have about the
study.
The project will be carried out in accordance with the
basic principles of the Declaration of Helsinki and ac-
cording to the legal regulations in effect (Royal Decree
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223/2004) and having obtained the pertinent approvals
from the reference CREC (Community of Madrid Pri-
mary Care and La Paz University Hospital, record
PI2011) and the approval of its viability by the Central
Committee on Research of the Primary Care Authorities
(record 05/2012).
As regards data confidentiality, the study will comply
with the terms laid down in the effective legislation: Or-
ganic Act 157/1999 of 13 December on Personal Data
Protection (Official State Gazette number 298 of 14 De-
cember 1999), dissociating the data that could identify
patients.
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